Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAF
Teresa Blasco, Maria; Navas, Carolina; Martin-Serrano, Guillermo; Grana-Castro, Osvaldo; Lechuga, Carmen G.; Martin-Diaz, Laura; Djurec, Magdolna; Li, Jing; Morales-Cacho, Lucia; Esteban-Burgos, Laura; Perales-Paton, Javier; Bousquet-Mur, Emilie; Castellano, Eva; Jacob, Harrys K. C.; Cabras, Lavinia; Musteanu, Monica; Drosten, Matthias; Ortega, Sagrario; Mulero, Francisca; Sainz Jr, Bruno; Dusetti, Nelson; Iovanna, Juan; Sanchez-Bueno, Francisco; Hidalgo, Manuel; Khiabanian, Hossein; Rabadan, Raul; Al-Shahrour, Fatima; Guerra, Carmen; Barbacid, Mariano
Publicación: CANCER CELL
2019
VL / 35 - BP / 573 - EP / +
abstract
Five-year survival for pancreatic ductal adenocarcinoma (PDAC) patients remains below 7% due to the lack of effective treatments. Here, we report that combined ablation of EGFR and c-RAF expression results in complete regression of a significant percentage of PDAC tumors driven by Kras/Trp53 mutations in genetically engineered mice. Moreover, systemic elimination of these targets induces toxicities that are well tolerated. Response to this targeted therapy correlates with transcriptional profiles that resemble those observed in human PDACs. Finally, inhibition of EGFR and c-RAF expression effectively blocked tumor progression in nine independent patient-derived xenografts carrying KRAS and TP53 mutations. These results open the door to the development of targeted therapies for PDAC patients.
Access level
Green accepted, Bronze
MENTIONS DATA
Publicaciones similares en Molecular Biology & Genetics
Publicaciones similares en Clinical Medicine
